Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CytomX Therapeutics Inc (NASDAQ: CTMX) and Array Biopharma (NASDAQ: ARRY).
CytomX Therapeutics Inc (NASDAQ: CTMX)
Oppenheimer analyst Leah R. Cann maintained a Hold rating on CytomX Therapeutics Inc (NASDAQ: CTMX) yesterday. The company’s shares closed yesterday at $24.40.
Cann noted:
“Our outlook for revenue from 2018 – 2025 is unchanged. We have slightly decreased our estimates for operating expense for 2019 – 2020, fine-tuned interest income, and modestly increased shares outstanding, which is decreasing estimated loss per share in 2019 – 2022 and decreasing estimated EPS in 2023 – 2025.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 9.1% and a 47.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.
CytomX Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $40.
See today’s analyst top recommended stocks >>
Array Biopharma (NASDAQ: ARRY)
In a report released yesterday, Mara Goldstein from Cantor Fitzgerald maintained a Buy rating on Array Biopharma (NASDAQ: ARRY), with a price target of $24. The company’s shares closed yesterday at $13.69.
Goldstein said:
“COLUMBUS at ASCO, BEACON at ESMO. ARRY is to present additional data from the COLUMBUS study at the ASCO meeting in June, and the updated results from the safety lead-in portion of the BEACON study at the ESMO Cancer, also in June. Based on results to-date, ARRY is exploring potential strategies to accelerate development, which we think would be a positive inflection point for the shares.”
According to TipRanks.com, Goldstein has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.2% and a 36.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, CytomX Therapeutics Inc, and Karyopharm Therapeutics.
Array Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $21.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
